-transparent.png){kind=logo}
The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-D-aspartate (NMDA)-subtype was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both diseases. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
January 1989,
Acta neurologica Belgica,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
June 1994,
Neuroreport,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
January 1991,
Neuroscience letters,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
June 2000,
European journal of pharmacology,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
July 2005,
Neuropharmacology,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
December 2003,
Alcoholism, clinical and experimental research,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
July 1993,
Brain research,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
August 1992,
European journal of pharmacology,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
September 1990,
British journal of pharmacology,
S Holemans, and
F Javoy, and
Y Agid, and
E C Laterre, and
J M Maloteaux
November 1988,
Neuroscience letters,
